NEURO-DEGENERATIVE DISEASES

Clinical trials for NEURO-DEGENERATIVE DISEASES explained in plain language.

Never miss a new study

Get alerted when new NEURO-DEGENERATIVE DISEASES trials appear

Sign up with your email to follow new studies for NEURO-DEGENERATIVE DISEASES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New oral drug enters human testing for devastating ALS

Disease control Not yet recruiting

This early-stage study is testing a new oral drug called Kamlanoflast in 40 people with ALS (amyotrophic lateral sclerosis). The main goals are to check if the drug is safe and tolerable when taken for 24 weeks, and to see how it affects markers of inflammation and physical funct…

Matched conditions: NEURO-DEGENERATIVE DISEASES

Phase: PHASE1, PHASE2 • Sponsor: Inflammasome Therapeutics • Aim: Disease control

Last updated Apr 01, 2026 14:41 UTC

NEURO-DEGENERATIVE DISEASES

Get alerted when new NEURO-DEGENERATIVE DISEASES trials appear

New oral drug enters human testing for devastating ALS